Brand name: ALIIVOSIDENIB
Composition:
Each tablet contains:
Ivosidenib……………………………………….250mg
Indication:
Newly diagnosed acute myeloid leukemia; Recurrent or refractory acute myeloid leukemia; Bile duct cancer.
Dosage:
• 500 mg orally once daily with or without food until disease progression or unacceptable toxicity. Avoid a high-fat meal.
• If the QTc interval increases to 480-500 milliseconds, the Ivosidenib dose is reduced or interrupted. For patients with prolonged QTc interval and life-threatening arrhythmia signs or symptoms, Ivosidenib needs to be permanently discontinued.
Contraindications: None.
Warning:
• Pregnant women, children and elderly patients should follow the doctor’s advice.
• Breastfeeding women should stop breastfeeding while taking medication.
• QTc Interval Prolongation
• Guillain-Barré Syndrome: Monitor patients for signs and symptoms of new
• motor and/or sensory findings. Permanently discontinue Ivosidenib in patients who are diagnosed with Guillain-Barré syndrome.
Adverse effects:
• The most common adverse events in patients with acute myeloid leukemia are fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, prolonged QT interval, rash, cough, loss of appetite, myalgia, constipation, and fever.
• The most common adverse reactions in patients with cholangiocarcinoma are fatigue, nausea, abdominal pain, diarrhea, cough, loss of appetite, ascites, vomiting, anemia, and rash.
Dosage form: Blue tablets.
Expiry date：24 months after date of manufacture.
Packaging: 60 tablets per bottle.
Storage:
• Store at room temperature 20-25℃.
• Keep out of reach of children.
DISCLAIMER
The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.
For your safety:
Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.
